BioSpace News Archive

OraSure Technologies, Inc. announced that its 2020 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT on Tuesday, May 19, 2020.

Mesoblast Limited announced that its Phase 3 trial of Revascor for advanced chronic heart failure has surpassed the number of primary endpoint events required for trial completion.

Funding will be used to support continued aggressive growth, diversification and further investment in the company’s proprietary technology platform

Triplet was formed by Atlas Venture and CEO Nessan Bermingham to create a new treatment paradigm for repeat expansion disorders

LHC Group, Inc.’s latest showing in two of the home health industry’s most coveted and highly valued measures of quality and performance demonstrate that the in-home healthcare provider’s results continue to surpass national averages and lead industry peers and competitors.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:^NBI), as part of the annual index evaluation.

Eli Lilly and Company (NYSE: LLY) today announced its 2020 financial guidance, highlighted by volume-based revenue growth and improving productivity, which are expected to result in operating margin expansion and strong earnings performance

ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval for mirvetuximab soravtansine

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line results from Cohort 2 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD).

Expanding behavioral health offerings helps increase access to mental well-being support and treatment